To include your compound in the COVID-19 Resource Center, submit it here.

Technology-agnostic diagnostics

Pathwork-Novartis: Pharma using partnering to build diagnostics platform

When Novartis AG launched its molecular diagnostics unit in late 2008, it said it would pursue partnerships for discovering and developing biomarkers to augment its internal capabilities. The pharma struck its second such collaboration last month, with Pathwork Diagnostics Inc., which will provide the ability to analyze expression of thousands of genes at once.

In the past 18 months, the molecular diagnostics unit has started 10 R&D programs, according

Read the full 688 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers